Pacira BioSciences (PCRX)
(Real Time Quote from BATS)
$14.34 USD
-0.19 (-1.31%)
Updated Sep 23, 2024 01:22 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
Pacira (PCRX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$20.11 | $39.00 | $8.00 | 38.40% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for Pacira comes to $20.11. The forecasts range from a low of $8.00 to a high of $39.00. The average price target represents an increase of 38.4% from the last closing price of $14.53.
Analyst Price Targets (9 )
Broker Rating
Pacira currently has an average brokerage recommendation (ABR) of 2.89 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 2.89 a month ago based on nine recommendations.
Of the nine recommendations deriving the current ABR, two are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 22.22% and 11.11% of all recommendations. A month ago, Strong Buy made up 22.22%, while Buy represented 11.11%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 5 | 6 |
Buy | 1 | 1 | 1 | 3 | 3 |
Hold | 4 | 4 | 4 | 1 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 2 | 2 | 2 | 0 | 0 |
ABR | 2.89 | 2.89 | 2.89 | 1.56 | 1.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/13/2024 | Truist Securities | Leszek Sulewski | Strong Buy | Strong Sell |
8/12/2024 | Piper Sandler | David Amsellem | Hold | Hold |
8/12/2024 | Not Identified | Not Identified | Moderate Buy | Hold |
8/12/2024 | Raymond James | Gary Nachman | Moderate Buy | Hold |
7/3/2024 | Not Identified | Not Identified | Strong Buy | Hold |
7/2/2024 | H.C. Wainwright & Co. | Oren Livnat | Strong Buy | Strong Buy |
7/2/2024 | Needham & Company | Serge Belanger | Moderate Buy | Moderate Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.89 |
ABR (Last week) | 2.89 |
# of Recs in ABR | 9 |
Average Target Price | $20.11 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 84 of 253 |
Current Quarter EPS Est: | 0.74 |
PCRX FAQs
Pacira BioSciences, Inc. (PCRX) currently has an average brokerage recommendation (ABR) of 2.89 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 9 brokerage firms.
The average price target for Pacira BioSciences, Inc. (PCRX) is $20.11. The current on short-term price targets is based on 7 reports.
The forecasts for Pacira BioSciences, Inc. (PCRX) range from a low of $8 to a high of $39. The average price target represents a increase of $38.40 from the last closing price of $14.53.
The current UPSIDE for Pacira BioSciences, Inc. (PCRX) is 38.40%
Based on short-term price targets offered by nine analysts, the average price target for Pacira comes to $20.11. The forecasts range from a low of $8.00 to a high of $39.00. The average price target represents an increase of 38.4% from the last closing price of $14.53.